Please use this identifier to cite or link to this item:
|Title:||Changes in the mRNA expression of osteoblast-related genes in response to β3-adrenergic agonist in UMR106 cells|
|Keywords:||Biochemistry, Genetics and Molecular Biology|
|Citation:||Cell Biochemistry and Function. Vol.28, No.1 (2010), 45-51|
|Abstract:||Activation of adrenergic receptors (AR) was demonstrated to result in either bone gain or bone loss depending on the activated AR subtypes and concentrations of agonists used. While β2-AR agonist was extensively investigated as an osteopenic agent, effects of β3-AR activation on osteoblasts were still elusive. Rat osteoblast-like UMR106 cells were herein found to express several AR subtypes, including β3-AR. After exposure to a low-dose β3-AR agonist BRL37344 (10 nmol L-1), UMR106 cells downregulated the mRNA expression of transcription factors Runx2 and Dlx5, which are important for initiation of osteoblast differentiation. Low-dose BRL37344 also decreased the expression ratio of receptor activator of nuclear factor kB ligand (RANKL) over osteoprotegerin (OPG), suggesting the protective effect of β3-AR agonist against bone resorption. Alkaline phosphatase expression was markedly decreased, whereas expressions of osteocalcin and osteopontin were increased by 100 nmol L-1 BRL37344, indicating that β3-AR activation could accelerate the transition of matrix maturation stage to mineralization stage. In conclusion, b3-AR activation in rat osteoblasts induced alteration in the expression of osteoblast-related transcription factor genes as well as genes required for bone formation and resorption. The present results also suggest that, besides β2-AR, β3-AR is another AR subtype responsible for the sympathetic nervous system-induced bone remodeling. Copyright © 2009 John Wiley & Sons, Ltd.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.